​
​

MoonLake Immunotherapeutics (MLTX) Revenue & Revenue Breakdown

OverviewForecastOwnershipFinancialsChart

MoonLake Immunotherapeutics Revenue Highlights

00

Main Segment (Y)

License

MoonLake Immunotherapeutics Revenue by Period

MoonLake Immunotherapeutics Revenue by Year

DateRevenueChange
2023-12-31-100.00%
2022-12-31-100.00%
2021-12-31-100.00%
2020-12-31--

MoonLake Immunotherapeutics generated - in revenue during NA 2023, up 100.00% compared to the previous quarter, and up 0.00% compared to the same period a year ago.

MoonLake Immunotherapeutics Revenue by Quarter

DateRevenueChange
2024-06-30-100.00%
2024-03-31--100.00%
2023-12-31$19.74K100.00%
2023-09-30-100.00%
2023-06-30-100.00%
2023-03-31-100.00%
2022-12-31-100.00%
2022-09-30-100.00%
2022-06-30-100.00%
2022-03-31-100.00%
2021-12-31-100.00%
2021-09-30-100.00%
2021-06-30-100.00%
2021-03-31--

MoonLake Immunotherapeutics generated - in revenue during Q2 2024, up 100.00% compared to the previous quarter, and up NaN% compared to the same period a year ago.

MoonLake Immunotherapeutics Revenue Breakdown

MoonLake Immunotherapeutics Revenue Breakdown by Product

Annual Revenue by Product

Product/ServiceDec 23Dec 22
License$299.60M$299.60M

MoonLake Immunotherapeutics's latest annual revenue breakdown by segment (product or service), as of Dec 23: License (100.00%).

Quarterly Revenue by Product

Product/ServiceSep 24Mar 24Dec 23Jun 23Mar 23Sep 22Jun 22
License$299.60M$299.60M-$299.60M$299.60M$302.10M$302.10M

MoonLake Immunotherapeutics's latest quarterly revenue breakdown by segment (product or service), as of Sep 24: License (100.00%).

MoonLake Immunotherapeutics Peer Comparison by Revenue

TickerCompanyLast Year RevenueLast Quarter Revenue
AMLXAmylyx Pharmaceuticals$380.79M$416.00K
TVTXTravere Therapeutics$145.24M$62.90M
ACLXArcellx$110.32M$26.03M
PLRXPliant Therapeutics$1.58M-
GPCRStructure Therapeutics--
NUVLNuvalent--
DAWNDay One Biopharmaceuticals-$20.07M
AVTEAerovate Therapeutics--
ABOSAcumen Pharmaceuticals--
CERECerevel Therapeutics--
TERNTerns Pharmaceuticals--
VTYXVentyx Biosciences--
ETNB89bio--
AKROAkero Therapeutics--
ELVNEnliven Therapeutics--
CMPXCompass Therapeutics--
MLTXMoonLake Immunotherapeutics--

MLTX Revenue FAQ

What is MoonLake Immunotherapeutics’s yearly revenue?

MoonLake Immunotherapeutics's yearly revenue for 2023 was $0, representing an increase of 100.00% compared to 2022. The company's yearly revenue for 2022 was $0, representing an increase of 100.00% compared to 2021. MLTX's yearly revenue for 2021 was $0, representing an increase of 100.00% compared to 2020.

What is MoonLake Immunotherapeutics’s quarterly revenue?

MoonLake Immunotherapeutics's quarterly revenue for Q2 2024 was $0, a 100.00% increase from the previous quarter (Q1 2024), and a 0% increase year-over-year (Q2 2023). The company's quarterly revenue for Q1 2024 was $0, a -100.00% decrease from the previous quarter (Q4 2023), and a 0% increase year-over-year (Q1 2023). MLTX's quarterly revenue for Q4 2023 was $19.74K, a 100.00% increase from the previous quarter (Q3 2023), and a 0% increase year-over-year (Q4 2022).

What is MoonLake Immunotherapeutics’s revenue growth rate?

MoonLake Immunotherapeutics's revenue growth rate for the last 3 years (2021-2023) was 0%

What are MoonLake Immunotherapeutics’s revenue streams?

MoonLake Immunotherapeutics's revenue streams in c 23 are License

What is MoonLake Immunotherapeutics’s main source of revenue?

For the fiscal year ending Dec 23, the largest source of revenue of MoonLake Immunotherapeutics was License. This segment made a revenue of $299.6M, representing 100.00% of the company's total revenue.